
Medications & Supplements
Metformin and Longevity
Metformin is the first-line drug for type 2 diabetes — a generic tablet the American Diabetes Association still calls effective, safe, inexpensive, and widely available 1.
That's why longevity medicine adopted it as its most promising candidate.
The aging case is less settled than its reputation: it rests on a 2014 observation two independent teams failed to reproduce, the largest multi-site mouse study found no lifespan extension, a 40-month monkey study found the opposite, and the trial designed to settle it hasn't launched.
Where the evidence holds up is metabolic — for people who have diabetes, and for people heading toward it.
- Reading time
- 8 min
- Source last reviewed
- 9 Aug 20269 Aug 2026
- Last updated
- 31 Aug 202631 Aug 2026
Longevity medicine has a weakness for exotic compounds, and metformin is the opposite of that — cheap, older than most of the people taking it, and the most commonly prescribed glucose-lowering drug in the world 3.
Why metformin became a longevity candidate
Four things made it the candidate. It has been prescribed since the 1950s 3 and is still where most people with type 2 diabetes start 1.
It has a randomized outcome trial behind it — in UKPDS, overweight patients on metformin had 32% fewer diabetes-related endpoints and 42% fewer diabetes-related deaths than those on diet alone 2.
Taking it is unremarkable: a generic tablet once or twice a day, stepped up slowly to keep the gut settled 1.
And it isn't a research chemical, which matters in a field where most candidates are.
The same trial's second randomization points the other way.
Adding metformin on top of a sulphonylurea was associated with a 96% higher risk of diabetes-related death 2 — a result left out of most summaries 3.
One more feature shapes the decision: there's nothing to feel. Nobody takes metformin because it makes their day go better, so the case rests entirely on the evidence.
What metformin does in the body
Its main effect is on the liver, where metformin reduces the glucose that gets made and released 4.
Past that the picture is unsettled: it works through both AMPK-dependent and AMPK-independent routes, where AMPK is AMP-activated protein kinase, a cellular fuel sensor that switches on when energy runs low, and much of the drug's effect now looks to happen in the gut 4.
AMPK is also where the aging hypothesis comes from.
It's part of the same nutrient-sensing machinery caloric restriction works on, which is the connection that put metformin in the aging conversation — see the science of aging for how those pathways fit together.
That bridge is built from mechanism, and the people who study it say the mechanisms remain complex and not fully understood 4.

The study that started the longevity case
The finding that launched all of this came out of a UK primary-care database in 2014.
Among roughly 180,000 people, those with type 2 diabetes started on metformin alone lived longer than matched people without diabetes — the comparison group's adjusted median survival ran about 15% shorter 5.
Diabetes takes years off life expectancy, so a drug that appears to close that gap looks like it's doing something past glucose control — and nearly everything downstream traces back to that inference.
Other groups went looking and found something else.
A Danish team working from national registers — including twin pairs where one twin developed diabetes and the other didn't, which holds family and genetics constant — found mortality about 50% higher in the metformin group than in the general population without diabetes, and about 90% higher among the twins, with the gap persisting after adjustment 6.
A twenty-year analysis of Welsh records found a benefit in the first three years that reversed after five 7.
The leading explanation is bookkeeping.
Metformin patients stopped being counted once their diabetes progressed enough to need a second drug, so the group was partly defined by doing well, and the controls were defined by never developing diabetes across the whole follow-up window 3.
Problems of that shape are called immortal time bias — the accounting favors the drug before anyone swallows a pill — and they turned a big observational signal on metformin and cancer into randomized trials that found nothing 8.
None of this shows metformin harming anyone: it shows people with diabetes dying sooner than people without it, the ordinary result.
The 2025 review assembling this record is candid that sensitivity analysis couldn't fully explain the gap 3.
The animal record runs both ways.
In the National Institute on Aging's Interventions Testing Program — one protocol run at three sites in genetically diverse mice — metformin alone didn't extend lifespan 9.
A 40-month study in male monkeys found it slowed multiple aging clocks and preserved brain structure and cognition 10. Both stand, and they don't agree.
| The claim | Evidence | The honest read |
|---|---|---|
| Metformin for type 2 diabetes | Established | First-line for decades. Cuts diabetes-related complications and death. Nothing in the aging debate touches this. |
| Metformin for prediabetes | Established | Cut progression to diabetes by 31%. In the same trial, diet and activity cut it by 58%. |
| Slowing aging biology | Early stage | No lifespan extension in the NIA's three-site mouse program. A monkey study found slowed aging clocks. Both stand. |
| Longer life without diabetes | Debated | The 2014 finding that started the field. Two independent teams found the opposite. |
| Better response to exercise | Debated | Two randomized trials in adults over 62 found the opposite — smaller gains in fitness and lean mass than placebo. |
The exercise question
The person most likely to be reading about metformin for longevity is also the person most likely to be training seriously, and the two trials that put those together came back the wrong way.
In the first, 53 adults averaging 62 took metformin or placebo through 12 weeks of aerobic training.
Both groups improved, but metformin blunted the gains in aerobic capacity and whole-body insulin sensitivity and wiped out the training-driven rise in muscle mitochondrial respiration 11.
The second was MASTERS: 94 healthy adults 65 and older took 1,700 mg a day or placebo through 14 weeks of supervised resistance training, and the placebo group gained more lean body mass and more thigh muscle 12.
Two things keep it in proportion.
The aerobic trial found highly variable responses, with positive and negative responders alike 11, and exercise still worked in every arm — metformin shrank the increment rather than cancelling the training.
The MASTERS investigators also went in expecting metformin to help, on the theory that damping inflammation lets older muscle grow better 12, which is the strongest sign the result isn't a stacked deck.
Why TAME still hasn't started
TAME — Targeting Aging with Metformin — is designed as six-year trials at 14 research institutions in more than 3,000 adults aged 65 to 79 13, testing metformin against one composite endpoint: death, cardiovascular events, cancer, and cognitive impairment together 314.
That endpoint is the point.
No trial has asked a regulator to treat age-related disease in aggregate as something a drug can be approved to delay, and if that precedent lands, every geroprotective drug behind metformin gets a road to travel 14.
The design has been prepared and reviewed; what the sponsor lists as still needed is funding to launch 13.
The one pilot that exists is MILES, the Metformin in Longevity Study: 14 adults around 70 took metformin for six weeks and placebo for six, and hundreds of genes shifted expression in muscle and fat, including pathways tied to aging 15 — a start at 14 people, not an answer.
Who the evidence fits
The strongest randomized evidence in people without diabetes belongs to one group: adults with prediabetes.
In the Diabetes Prevention Program, metformin cut progression to type 2 diabetes by 31% over about three years among participants whose average body mass index was 34.
The same trial's diet-and-activity arm cut it by 58% 16, which is the honest comparison.
If you're metabolically healthy and already training, the closest randomized evidence to your situation is the exercise work, and it points the other way.
If you don't know which group you're in, bloodwork answers that, and continuous glucose monitoring can add texture to a fasting number.
Metformin is generic and off-label prescribing is legal and routine, which is why it turns up in longevity practices and telehealth.
No longevity dose has been established. A clinician watches three things:
- kidney function, since the drug isn't used once filtration drops below a set threshold 1;
- vitamin B12, which long-term use depletes — borderline-low levels ran 19.1% on metformin against 9.5% on placebo at five years in the diabetes-prevention cohort 17;
- and the gut, the common reason people quit, with diarrhea in 53% against 12% on placebo in the label's trial data, usually eased by slow titration and food 181.
Metformin also carries a boxed warning for lactic acidosis; the label notes those cases occurred primarily in people with significant kidney impairment 18.
The label adds one calibration: no clinical studies have established conclusive evidence that metformin reduces macrovascular risk 18.
What's worth bringing to a clinician handling off-label longevity care is specific — what target, what counts as a response, what gets monitored.
Choosing that clinician is a separate question.
Bottom line
Metformin is a good drug with an uncertain second career.
The metabolic case holds up and is cheap to act on: it treats type 2 diabetes and delays it in people with prediabetes, though diet and activity delayed it more.
The reason it entered the longevity conversation hasn't held up, and what's still open is whether the monkey result means anything for people.
Metformin is proven for a metabolic problem and unproven for aging — and for a fit, healthy reader, the trials closest to your situation point the wrong way.
The useful question isn't whether metformin works. It's whether you're in the group it has been shown to help, and that's something your labs and a clinician can settle together.
Sources and references18 sources
- 1
American Diabetes Association Professional Practice Committee. "9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026." Diabetes Care. 2026;49(Suppl 1):S183. Diabetes Care ↑
- 2
UK Prospective Diabetes Study (UKPDS) Group. "Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)." The Lancet. 1998;352(9131):854-865. PubMed ↑
- 3
Keys MT, Hallas J, Miller RA, Suissa S, Christensen K. "Emerging uncertainty on the anti-aging potential of metformin." Ageing Research Reviews. 2025;111:102817. PubMed ↑
- 4
Rena G, Hardie DG, Pearson ER. "The mechanisms of action of metformin." Diabetologia. 2017;60(9):1577-1585. PubMed ↑
- 5
Bannister CA, Holden SE, Jenkins-Jones S, et al. "Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls." Diabetes, Obesity and Metabolism. 2014;16(11):1165-1173. PubMed ↑
- 6
Keys MT, Thinggaard M, Larsen LA, Pedersen DA, Hallas J, Christensen K. "Reassessing the evidence of a survival advantage in Type 2 diabetes treated with metformin compared with controls without diabetes: a retrospective cohort study." International Journal of Epidemiology. 2022;51(6):1886-1898. PubMed ↑
- 7
Stevenson-Hoare J, Leonenko G, Escott-Price V. "Comparison of long-term effects of metformin on longevity between people with type 2 diabetes and matched non-diabetic controls." BMC Public Health. 2023;23:804. PubMed ↑
- 8
Yu OHY, Suissa S. "Metformin and Cancer: Solutions to a Real-World Evidence Failure." Diabetes Care. 2023;46(5):904-912. PubMed ↑
- 9
Strong R, Miller RA, Antebi A, et al. "Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α-glucosidase inhibitor or a Nrf2-inducer." Aging Cell. 2016;15(5):872-884. PubMed ↑
- 10
Yang Y, Lu X, Liu N, et al. "Metformin decelerates aging clock in male monkeys." Cell. 2024;187(22):6358-6378. PubMed ↑
- 11
Konopka AR, Laurin JL, Schoenberg HM, et al. "Metformin inhibits mitochondrial adaptations to aerobic exercise training in older adults." Aging Cell. 2019;18(1):e12880. PubMed ↑
- 12
Walton RG, Dungan CM, Long DE, et al. "Metformin blunts muscle hypertrophy in response to progressive resistance exercise training in older adults: A randomized, double-blind, placebo-controlled, multicenter trial: The MASTERS trial." Aging Cell. 2019;18(6):e13039. PubMed ↑
- 13
"The TAME Trial." American Federation for Aging Research. AFAR ↑
- 14
Barzilai N, Crandall JP, Kritchevsky SB, Espeland MA. "Metformin as a Tool to Target Aging." Cell Metabolism. 2016;23(6):1060-1065. PubMed ↑
- 15
Kulkarni AS, Brutsaert EF, Anghel V, et al. "Metformin regulates metabolic and nonmetabolic pathways in skeletal muscle and subcutaneous adipose tissues of older adults." Aging Cell. 2018;17(2):e12723. PubMed ↑
- 16
Knowler WC, Barrett-Connor E, Fowler SE, et al.; Diabetes Prevention Program Research Group. "Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin." New England Journal of Medicine. 2002;346(6):393-403. PubMed ↑
- 17
Aroda VR, Edelstein SL, Goldberg RB, et al.; Diabetes Prevention Program Research Group. "Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study." Journal of Clinical Endocrinology & Metabolism. 2016;101(4):1754-1761. PubMed ↑
- 18
"Metformin Hydrochloride Tablets — Prescribing Information." U.S. Food and Drug Administration / DailyMed, National Library of Medicine. DailyMed ↑
Build your starting plan.
A few short questions, about two minutes. The Blueprint recommends where to start and explains why.
Build my Blueprint